Agustí Alvar
Institut del Tòrax, Hospital Clínic, Universitat de Barcelona, CIBER Enfermedades Respiratorias, Fundación Caubet-Cimera, Illes Balears, España.
Arch Bronconeumol. 2009;45 Suppl 4:14-7. doi: 10.1016/S0300-2896(09)72858-3.
Patients with chronic obstructive pulmonary disease (COPD) frequently have other chronic diseases (comorbidity) that worsen their clinical status and prognosis. Systemic inflammation may be an important pathogenic factor. The present article critically reviews some of the less well known areas in this context. For example, there is no clear definition of systemic inflammation in COPD, its prevalence is highly dependent on the inflammatory marker (or combination of markers) used in its identification, its origin is probably multifactorial and the evidence supporting an association between systemic inflammation and the presence of comorbidity in COPD is circumstantial. Finally, although several studies have evaluated the effect of inhaled glucocorticosteroids on systemic inflammation, the results are contradictory. Therefore, the association between systemic inflammation and comorbidity in COPD is a tempting, but unproven, one.
慢性阻塞性肺疾病(COPD)患者常伴有其他慢性疾病(合并症),这些合并症会使他们的临床状况和预后恶化。全身炎症可能是一个重要的致病因素。本文批判性地综述了这方面一些不太为人所知的领域。例如,COPD中全身炎症尚无明确的定义,其患病率高度依赖于用于识别的炎症标志物(或标志物组合),其起源可能是多因素的,而且支持COPD中全身炎症与合并症存在关联的证据是间接的。最后,尽管有几项研究评估了吸入糖皮质激素对全身炎症的影响,但其结果相互矛盾。因此,COPD中全身炎症与合并症之间的关联是一个诱人但未经证实的关联。